Quince Therapeutics, Inc. (QNCX): Nasdaq/NYSE listing notice — Quince Therapeutics receives two Nasdaq deficiency notices with 180-day cure periods

Quince Therapeutics, Inc.

Bid Price Notice: common stock closing bid below $1.00 for 30 consecutive business days; cure by Sept 14, 2026.
MVLS Notice: market value of listed securities below $50M for 30 consecutive business days; cure by Sept 14, 2026.
To regain compliance, bid price must close at $1+ for 10 consecutive days, or MVLS at $50M+ for 10 consecutive days.
If not cured by deadline, company may transfer to Nasdaq Capital Market or face delisting.
Stock continues trading on Nasdaq under symbol QNCX during cure period.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Quince Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

March 16, 2026, Quince Therapeutics, Inc. (the “Company”) received a notice (the “Bid Price Notice”) from the Nasdaq Listing Qualifications department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the closing bid price of the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Company has a period of 180 calendar days, or until September 14, 2026 (the “Compliance Date”), to regain compliance with the Minimum Bid

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-117794

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.